SARS-CoV Infection
Conditions
Keywords
COVID-19, Remdesivir
Brief summary
Remdesivir is a monophosphoramidate prodrug of an adenosine analogue and it has a broad-spectrum antiviral activity against paramyxoviruses, falviviruses and coronaviruses. It showed in vitro activity on human airway epithelial cells against SARS-CoV-2. It is an investigational drug and granted an Emergency Use Authorization by Food and Drug Administration FDA, so it is under clinical trial. The potent mechanism of action of this drug is still unclear but it effects through several processes. It can interfere with nsp12 polymerase even when exoribonuclease proofreading is intact. It can also produce nucleoside triphosphate NTP that acts pharmacologically active alternate substrate of RNA-chain terminator, as a result NTP can constrain active triphosphates into viral RNA of coronaviruses. There is evidence of high genetic barrier to develop resistance against Remdesivir in coronavirus as a result of which is maintains its effectiveness in antiviral therapies against these viruses. Effectiveness of Remdesivir has been reported against different groups of coronaviruses including Alphacoronavirus NL63 and several SARS/MERS-CoV coronaviruses.
Detailed description
This is interventional single-center study, that will be done at Lahore General Hospital in which 95 beds are allocated for COVID-19 patients including ICUs and HDUs. Ethical approval will be obtained from research ethical committee of Lahore General hospital, Lahore. Informed consent will be obtained from all patients who will agree to publish their data in this research. Patient's privacy protection will be obeyed with the Helsinki Declaration. The aim of this study is to evaluate clinical effectiveness of this investigational drug, started a clinical trial of this drug on laboratory-confirmed COVID-19 patients at a tertiary care hospital of Lahore, Pakistan.
Interventions
DRUGRemdesivir
200 mg I/v Remdesivir will be given to moderate disease patients of COVID-19. It will be loading dose then 100 mg I/V dose will be given for 5 days. Customized decision for Remdesivir dosage will be made by attending infectious diseases physician, comfort with usage, bacterial co-infection and duration of Ventilation and dose will be extended up to 10 days according to clinical condition of the patients.
Sponsors
Lahore General Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Qausi-experimental
Eligibility
Sex/Gender
ALL
Age
15 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* All patients of all ages, males, and females who will be diagnosed COVID-19 positive by RT-PCR with moderate illness. * Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT chest. * Respiratory rate \> 22/ min and \>50% of radiological involvement of lung with typical lesions. * FiO2 remain static or improving along with \> 30% deranged ≥ 2 biochemical markers CRP \> 20 mg/l, LDH \> 600 U/L, D.Dimer \> 0.5mg/l or 500 ng/ml, Serum Ferritin \< 500 ng/ml or mcg/l will be included in clinical trial.
Exclusion criteria
* Patients on Invasive mechanical ventilation (IMV). * Patients with respiratory rate \< 20/mins and whose laboratory findings will not be deranged \> 20%. * Presences of chronic renal failure \> 4 stage, GFR \< 30ml/min/1.73m2. * ALT/AST \> 5 times than normal values. * Pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response after administration | 10 days | Clinical improvement of COVID-19 patients by Remdesivir. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response to treatment | 15 days | Overall survival of COVID-19 patients after drug administration. |
| Duration of hospitalization | 15 days | Number of days of hospital admission either in ICU or HDUs till date of discharge |
| Supplemental Oxygen Requirement from Baseline | 15 days | Duration of increased supplemental oxygen requirement from baseline |
Countries
Pakistan
Contacts
Primary ContactMuhammad Irfan Malik, FCPS
Backup ContactSardar Al-Fareed Zafar, FCPS
Outcome results
None listed